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Objectives:  
Osteoarthritis (OA) is a common joint disorder that affects millions of people all around the world. The etiology of OA, 
however, is still poorly understood. Recent studies have suggested that adipokines play important roles in the 
pathogenesis of OA. Fatty acid binding protein 4 (FABP4) is a novel adipokine that is closely associated with obesity and 
metabolic diseases. Yet no previous studies have examined FABP4 in OA. The aim of this study is to explore the potential 
role of FABP4 in the pathogenesis of OA. 
 
Methods: 
Both clinical study and animal study were performed. For the clinical study, we included patients with radiologically-
confirmed knee OA and non-OA controls. Plasma level of FABP4 was determined by ELISA method. Regression analysis of 
FABP4 and knee OA severity, which was presented as Kellgren-Lawrence (K-L) grade was performed. For the animal study, 
we included 36 FABP4 knockout mice (KO) and 36 wild-type littermates (WT) (all male, 6-week-old), and fed the mice with 
a very high-fat diet (HFD, fat 60% calorie) or standard diet (STD, fat 11.6% calorie), for 3 months, 6 months and 9 months. 
At each time point, we measured animals’ body weight and body fat. We then evaluated knee OA via examination of 
serum Cartilage Oligomeric Matric Protein (COMP) level, knee histologic assessment, and subchondral bone analyses. In 
the parallel study, we included 48 WT mice and fed the mice with HFD or STD, and simultaneously treated them with daily 
oral gavage of FABP4 selective inhibitor BMS309403 (15mg/kg/d) or vehicle (PBS solution), for 4 months and 6 months. At 
each time point, OA evaluation was performed same as above.  
 
Results: 
A total of 226 patients were included. 58 were males and 168 were females. The mean plasma level of non-OA patients, 
KL-2 patients, KL-3 patients, and KL-4 patients were 12.33.0 ng/ml (n=6), 14.66.9 ng/ml (n=72), 18.211.3 ng/ml 
(n=65), and 19.312.3 ng/ml (n=83), respectively (p=0.023, one-way ANOVA). After stratifying FABP4 into 4 level groups 
(<10 ng/ml, 10-15 ng/ml, 15-20 ng/ml, >20 ng/ml), FABP4 was positively associated with the severity of knee OA (p=0.031, 
ordinal regression analysis, age and sex adjusted). (Figure 1) For the animal study, HFD induced significant obesity in mice. 
However, KO mice were much fatter than WT mice with significantly higher body weight and higher percent body fat. 
(Figure 2) At 3 months of HFD, KO mice showed less cartilage degradation than WT mice with significantly lower serum 
COMP ((1.6±0.2)U/L vs (2.3±0.3) U/L, p=0.01) and OARSI score ((0.80.4) vs (2.90.4), p=0.00). Daily oral gavage of 
BMS309403 in mice for 4 months protected cartilage from degradation as well, in which the mice with BMS309403 for 4 
months showed significantly lower COMP ((1.7±0.2)U/L vs (2.1±0.3) U/L, p=0.04) and OARSI score (5.46.0 vs 6.00.4, 
p=0.04) than mice with PBS. (Figure 3) At 9 months of HFD, WT mice underwent serious OA changes with significant 
osteophyte formation and subchondral bone sclerosis. While in KO mice, the changes were much alleviated. The 
subchondral bone BMD (p=0.00), bone volume percentage (p=0.00), trabecular thickness (p=0.00), and trabecular 
number (p=0.01) was significantly lower in KO mice. However, chronic treatment with BMS309403 did not seem to have 
significant effects on the subchondral bone strcuture. (Figure 4) For lean mice (fed with STD), either genetically knocking 
out or pharmaceutical inhibition of FABP4 had no significant effects on knee OA.  
 
Conclusions: 
Plasma FABP4 level was positively associated with the severity of knee OA. Knocking out or pharmaceutical inhibition of 
FABP4 alleviated OA induced by a very high-fat diet in mice. FABP4 may be a potential biomarker for knee OA. 
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Figure 1 Serum FABP4 level in 6 non-OA patients and 220 radiologically-confirmed OA patients. The level was 12.33.0 
ng/ml, 14.66.9 ng/ml, 18.211.3 ng/ml, and 19.312.3 ng/ml in KL-0, KL-2, KL-3, and KL-4, respectively (p=0.023, one-
way ANOVA). Post hoc analyses showed FABP4 of KL-2 patients was significantly lower than KL-4 patients (p=0.028, Tukey 
HSD).  After stratifying FABP4 into 4 level groups (<10 ng/ml, 10-15 ng/ml, 15-20 ng/ml, >20 ng/ml), the ordinal regression 
analysis showed that FABP-4 was positively associated with the severity of knee OA (p=0.031, age and sex adjusted).  
 
                                                      
 
F igure 2 Knocking out or pharmaceutical inhibition of FABP4 significantly increased animals’ body weight and body fat 
percentage. (A) Photos of KO and WT mice after 6-month of HFD and STD showed KO mice were fatter than WT mice, 
especially under HFD. (B, C) Statistical analyses showed KO mice had significantly higher body weight and body fat.  (C) WT 
mice treated with daily oral gavage of BMS309403 (15mg/kg/d) for 4 months and 6 months had significantly higher body 
weight and body fat.  
 
 
 
F igure 3 Knocking out or pharmaceutical inhibition of FABP4 significantly alleviated cartilage degradation in mice fed 
with HFD. The coronal paraffin sections of knees were stained with Safranin O and Fast Green. Loss of Safranin O staining 
in cartilage indicated a loss of glycosaminoglycan (GAG) content. (A, D, A1, D1) KO and WT mice after 3-month of HFD. 
Staining loss of cartilage was observed in WT mice but not obviously seen in KO mice. (B, E, B1, E1) KO and WT mice after 
6-month of HFD. KO mice started to undergo cartilage degradation, while in WT mice the cartilage were seriously 
degenerated. In addition, osteophyte formation was seen in WT mice, especially in the medial compartment (arrow). (C, F, 
C1, F1) KO and WT mice after 9-month of HFD. Both KO and WT mice experienced severe cartilage degradation. In WT 
mice, serious subchondral bone sclerosis was observed (arrow). (G, I, G1, I1) WT mice treated with BMS309403 or PBS for 
4 months. Mice treated with BMS309403 showed less cartilage staining loss than mice treated with PBS.  (H, J, H1, J1) WT 
mice treated with BMS309403 or PBS for 6 months. Mice with PBS showed significant cartilage staining loss. (K) KO mice 
showed significantly lower level of COMP than WT mice after 3-month of HFD and STD. COMP level at 6-month of HFD in 
KO mice was significantly higher than WT, which suggested severe cartilage degradation in WT mice. (L) The OARSI score 
was significantly lower in KO mice than WT mice. (M) Mice treated with BMS309403 for 4 months showed significantly 
lower serum COMP than mice with PBS. (N) The OARSI score was significantly lower in mice treated with BMS309403 for 4 
months. (Data presented as meanstd. Student t-test was performed to compare the means. *: p<0.05.) 
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F igure 4. Micro-CT analysis of subchondral bone. Knocking out FABP4 significantly alleviated subchondral bone sclerosis 
in mice fed with HFD for 6 months and 9 months (A, arrow indicated). The subchondral bone BMD (p=0.00), bone volume 
percentage (p=0.00), trabecular thickness (p=0.00), and trabecular number (p=0.01) was significantly lower in KO mice 
after 9-month of HFD. (C, D, E, F) However, chronic treatment of BMS309403 in WT mice for 4 months and 6 months did 
not seem to have significant effects on the subchondral bone. (B, G, H, I, J) (**:p<0.01) 
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